Dna X, Inc. (SONM) Stock Price & Analysis

Dna X, Inc. (SONM) fell 4.19% to USD 4.8 as of June 10, 2026 at 04:57 UTC, according to Nexqual real-time market data.

SONM last closed at USD 5.01; the session ranged USD 4.8–5.05 on volume of 9,990 shares. Market capitalization is $7.14M, with a 52-week range of USD 2.52–38.52 (NCM). Source: Nexqual, June 10, 2026 at 04:57 UTC.

Key Statistics (as of June 10, 2026 at 04:57 UTC)

PriceUSD 4.8
Change▼ 4.19% (down)
Previous CloseUSD 5.01
OpenUSD 4.96
Day RangeUSD 4.8 – 5.05
52-Week RangeUSD 2.52 – 38.52
Volume9,990 shares
Market Cap$7.14M
ExchangeNCM

Technical Analysis (SONM)

Nexqual's technical model rates SONM "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 04:57 UTC.

Overall SignalSTRONG BUY
RSI (14)55.89 (neutral)
vs SMA50Above (USD 4.25)
MACD0.12 (positive)

Analyst Ratings (SONM)

Wall Street analysts rate SONM "None", per Nexqual as of June 10, 2026 at 04:57 UTC.

Consensus RatingNone

Earnings (SONM)

Recent Earnings History

QuarterActual vs Estimate
2024-09-30USD -9.36 vs est -11.88 ▲ beat
2024-06-30USD -25.38 vs est -9.72 ▼ miss
2024-03-31USD -12.6 vs est -5.4 ▼ miss

Source: Nexqual, June 10, 2026 at 04:57 UTC.

Financials & Fundamentals (SONM)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
Current Ratio0.76
Total Cash$1.20M
Total Debt$1.07M
Free Cash Flow$-6.97M

Source: Nexqual, June 10, 2026 at 04:57 UTC.

Financial Health Score (SONM)

Nexqual rates Dna X, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:57 UTC.

GrowthCritical — Revenue -100% YoY (annual), sharp decline
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetMixed — $1M cash vs $1M debt, net cash position
Cash FlowWeak — Operating cash flow -$17M
EfficiencyMixed — No data

Ownership (SONM)

Insider Ownership+37.34%
Institutional Ownership+6.40%
Shares Outstanding1.49M
Float1.21M
Short % of Float+4.46%

Source: Nexqual, June 10, 2026 at 04:57 UTC.

Leadership (SONM)

Dna X, Inc. is led by Michael C. Mulica (age 62), Executive Chairman & Acting CEO, per Nexqual as of June 10, 2026 at 04:57 UTC.

Executive Chairman & Acting CEOMichael C. Mulica (age 62)
Chief Financial OfficerClayton Crolius (age 62)
Senior Vice President of Global OperationsZhide Wang
Senior Vice President of Sales & Customer ExperienceDyan Kaplan
Vice President of MarketingAnette Gaven

Major Backers & Investors (SONM)

Notable institutional backers of Dna X, Inc. include UBS Group AG, C2c Wealth Management, LLC , Fidelity, according to Nexqual as of June 10, 2026 at 04:57 UTC.

Active Investors

InvestorStake
UBS Group AG2.43%
C2c Wealth Management, LLC 1.34%
Fidelity0.99%

Index Funds (Passive)

FundStake
Geode Capital0.99%
Vanguard Group0.96%
BlackRock0.94%

Source: Nexqual, June 10, 2026 at 04:57 UTC.

From Dna X, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
FAMIFarmmi, Inc. Ordinary SharesUSD 1.12▼ 1.75%
GRNQGreenpro Capital Corp.USD 1.51▼ 1.31%
SXTCChina SXT Pharmaceuticals, Inc.USD 1.56▲ 8.33%
DATSDatChat, Inc.USD 2.66▲ 16.96%
WORXSCWorx Corp.USD 0.26▼ 24.43%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:57 UTC. This page is informational and not investment advice.